Clinical application of serological gastric biopsy in the screening of gastric precancerous disease

Abstract

Objective To analyze the correlation between gastric mucosa serological biopsy ［serum pepsinogen Ⅰ（PGⅠ）, pepsinogen Ⅱ（PGⅡ）, ratio of PGⅠ/PGⅡ(PGR), gastrin-17 and helicobacter pyloriantibody（HP-IgG）］ and histological gastritis evaluation criteria （OLGA/OLGIM）, and to evaluate the efficacy of these indicators in the screening of gastric precancerous disease. Methods A total of 417 patients underwent gastroscopy for dyspepsia were selected in the 971st Hospital of the PLA Navy from January 2019 to December 2021 were selected. They were evaluated in groups according to the OLGA/OLGIM staging system, and the serum PGⅠ, PGⅡ, PGR, G-17 and HP-IgG were detected and analyzed. Results In OLGA/OLGIM group, PGⅠ and PGR decreased with the increase of group grade(P＜0.01), while the infection rates of G-17 and HP increased with the increase of group grade(P＜0.01). Kendall correlation analysis showed that there was a positive correlation between the combined scoring method and OLGA stage and OLGIM stage (r=0.44, 0.43,P<0.01). In addition, the levels of PGⅡ and G-17 in HP-IgG positive group were significantly higher than those in the negative group, and the levels of PGⅠ and PGR were significantly lower than those in the negative group (P＜0.01). Conclusion Serological gastric biopsy is closely related to OLGA/OLGIM stage, which shows great potential in the screening and evaluation of gastric precancerous disease.

Keywords

• pepsinogen
• gastrin
• helicobacter pylori antibody
• gastric precancerous disease
• screening
• serological biopsy